Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients
Introduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2016-08-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/7542 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313764739907584 |
|---|---|
| author | Luciana Brosina de Leon Cristiane Valle Tovo Dimas Alexandre Kliemann Angelo Alves de Mattos Alberi Adolfo Feltrin Liliane Souto Pacheco Paulo Roberto Lerias de Almeida |
| author_facet | Luciana Brosina de Leon Cristiane Valle Tovo Dimas Alexandre Kliemann Angelo Alves de Mattos Alberi Adolfo Feltrin Liliane Souto Pacheco Paulo Roberto Lerias de Almeida |
| author_sort | Luciana Brosina de Leon |
| collection | DOAJ |
| description | Introduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some countries. To know the impact of such medications in the sustained virological response (SVR) during HCV treatment is of great importance.
Methodology: This was a retrospective cohort study of 215 coinfected HIV/HCV patients. The patients were treated with PEG-IFN and RBV between 2007 and 2013 and analyzed by intention to treat. Treatment-experienced patients to HCV and carriers of hepatitis B were excluded. Demographic data (gender, age), mode of infection, HCV genotype, HCV viral load, hepatic fibrosis, HIV status, and type of PEG were evaluated. One hundred eighty-eight (87.4%) patients were using HAART.
Results: SVR was achieved in 55 (29.3%) patients using HAART and in 9 (33.3%) patients not using HAART (p = 0.86). There was no difference in SVR between different HAART medications and regimens using two reverse transcriptase inhibitor nucleosides (NRTIs) or the use of protease inhibitors and non-NRTIs (27.1% versus 31.5%; p = 0.61). The predictive factors for obtaining SVR were low HCV viral load, non-1 genotype, and the use of peginterferon-α2a.
Conclusions: The use of HAART does not influence the SVR of HCV under PEG-IFN and RBV therapy in HIV/HCV coinfected patients.
|
| format | Article |
| id | doaj-art-d18d1fa266af4d7d9c31d31f4d008f46 |
| institution | Kabale University |
| issn | 1972-2680 |
| language | English |
| publishDate | 2016-08-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-d18d1fa266af4d7d9c31d31f4d008f462025-08-20T03:52:41ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802016-08-01100710.3855/jidc.7542Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patientsLuciana Brosina de Leon0Cristiane Valle Tovo1Dimas Alexandre Kliemann2Angelo Alves de Mattos3Alberi Adolfo Feltrin4Liliane Souto Pacheco5Paulo Roberto Lerias de Almeida6Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, BrasilUniversidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, BrasilUniversidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, BrasilUniversidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, BrasilHospital Nossa Senhora da Conceição, Porto Alegre, BrasilHospital Nossa Senhora da Conceição, Porto Alegre, BrasilUniversidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, BrasilIntroduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some countries. To know the impact of such medications in the sustained virological response (SVR) during HCV treatment is of great importance. Methodology: This was a retrospective cohort study of 215 coinfected HIV/HCV patients. The patients were treated with PEG-IFN and RBV between 2007 and 2013 and analyzed by intention to treat. Treatment-experienced patients to HCV and carriers of hepatitis B were excluded. Demographic data (gender, age), mode of infection, HCV genotype, HCV viral load, hepatic fibrosis, HIV status, and type of PEG were evaluated. One hundred eighty-eight (87.4%) patients were using HAART. Results: SVR was achieved in 55 (29.3%) patients using HAART and in 9 (33.3%) patients not using HAART (p = 0.86). There was no difference in SVR between different HAART medications and regimens using two reverse transcriptase inhibitor nucleosides (NRTIs) or the use of protease inhibitors and non-NRTIs (27.1% versus 31.5%; p = 0.61). The predictive factors for obtaining SVR were low HCV viral load, non-1 genotype, and the use of peginterferon-α2a. Conclusions: The use of HAART does not influence the SVR of HCV under PEG-IFN and RBV therapy in HIV/HCV coinfected patients. https://jidc.org/index.php/journal/article/view/7542HIVHCVpeginterferonHAARTtherapy |
| spellingShingle | Luciana Brosina de Leon Cristiane Valle Tovo Dimas Alexandre Kliemann Angelo Alves de Mattos Alberi Adolfo Feltrin Liliane Souto Pacheco Paulo Roberto Lerias de Almeida Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients Journal of Infection in Developing Countries HIV HCV peginterferon HAART therapy |
| title | Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients |
| title_full | Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients |
| title_fullStr | Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients |
| title_full_unstemmed | Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients |
| title_short | Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients |
| title_sort | antiretroviral therapy does not affect response to chronic hepatitis c therapy in hiv coinfected patients |
| topic | HIV HCV peginterferon HAART therapy |
| url | https://jidc.org/index.php/journal/article/view/7542 |
| work_keys_str_mv | AT lucianabrosinadeleon antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT cristianevalletovo antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT dimasalexandrekliemann antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT angeloalvesdemattos antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT alberiadolfofeltrin antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT lilianesoutopacheco antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients AT paulorobertoleriasdealmeida antiretroviraltherapydoesnotaffectresponsetochronichepatitisctherapyinhivcoinfectedpatients |